Z
Zentera Therapeutics
Clinical-stage oncology therapeutics for the Chinese market
About Zentera Therapeutics
Zentera Therapeutics is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, that focuses on developing and commercializing oncology treatments. The company was established in May 2020 as a joint venture by its US-based parent company, Zentalis Pharmaceuticals, to bring cancer therapies to the Chinese market. Dr. Anthony Sun, the CEO of Zentalis, also serves as the CEO of Zentera. The formation was initiated with a $20 million Series A financing led by Tybourne Capital Management and OrbiMed Asia. This was followed by a $75 million Series B financing in August 2021 to further advance clinical development.
The company's business model is centered on licensing and developing a pipeline of oncology candidates discovered by Zentalis specifically for the Greater China market. Zentera has operations in Shanghai and Beijing and aims to become a leading biopharmaceutical firm in China. Its pipeline includes small molecule therapeutics targeting fundamental biological pathways in cancers. Key product candidates under development include Azenosertib (ZN-c3), a WEE1 inhibitor for solid tumors; ZN-c5, an oral Selective Estrogen Receptor Degrader (SERD) for ER+/HER2- breast cancer; and Asaretoclax (ZN-d5), a BCL-2 inhibitor for hematologic malignancies. The company strategy involves participating in global clinical trials with Zentalis and potentially in-licensing additional oncology assets for development. Recently, Zentalis announced the discontinuation of the development of ZN-d5 in combination with azenosertib.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2021 | $75M | $300M | Farallon Capital Management · Viking Global Investors · Redmile Group · Perceptive Advisors | — |
| SERIES AOther financing | May 2020 | $20M | $80M | Tybourne Capital Management · OrbiMed | ↗ |
Growth signals
Latest recorded traffic for Zentera Therapeutics is 250 monthly website visits. Zentera Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zentera Therapeutics in its local ecosystem
The Zentera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Tybourne Capital Management
OrbiMed
Farallon Capital Management
Viking Global Investors
Redmile Group
Perceptive Advisors
Logos Capital
Casdin Capital
Lilly Asia Ventures
Avidity Partners
Surveyor Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zentera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zentera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









